Heart Failure with Reduced Ejection Fraction
📧 Sign up to get email alerts when something new happens for Heart Failure with Reduced Ejection Fraction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-05-20Clinical Trial Update: Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. [Phase 4]
Phase 4 trial evaluating prophylactic lisinopril for anthracycline-induced cardiomyopathy has been withdrawn.
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension [Phase 2, Phase 3]
This clinical trial update outlines Phase 2 and Phase 3 studies evaluating midodrine in patients with heart failure with reduced ejection fr…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Colchicine in Acutely Decompensated HFREF [Phase 4]
A Phase 4 clinical trial evaluating colchicine for acutely decompensated heart failure with reduced ejection fraction. The study is currentl…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Effects of a Single Oral Dose of KETone Ester ON Exercise Performance in Patients With Chronic Heart Failure [NA]
A completed clinical trial evaluated whether a single oral dose of a ketone ester affects exercise performance in patients with chronic hear…
-
CLINICAL_TRIALS withdrawal · 2024-05-01Clinical Trial Update: Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure [NA]
A clinical trial evaluating email reminders to improve GDMT adherence for mineralocorticoid receptor antagonists in heart failure with reduc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency [Phase 4]
A Phase 4 trial evaluating SGLT2 inhibitors for heart failure with reduced ejection fraction in patients with chronic kidney disease has bee…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF) [Phase 4]
Phase 4 trial update on dapagliflozin in acute heart failure with reduced ejection fraction assessing clinical outcomes.
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: Determination of Drug Levels for Pharmacotherapy of Heart Failure [Phase 4]
A Phase 4 trial update focusing on determining drug levels for pharmacotherapy in heart failure with reduced ejection fraction.
-
FDA approval · 2024-01-18FDA Approved: BISOPROLOL FUMARATE — Original Application (Harman Finochem Limited)
FDA approved Harman Finochem Limited's bisoprolol fumarate as an original generic application (ANDA). Bisoprolol fumarate is a beta-blocker …
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Pulse Reduction On Beta-blocker and Ivabradine Therapy [Phase 4]
A Phase 4 clinical trial update evaluating pulse reduction on beta-blocker and ivabradine therapy in patients with dilated cardiomyopathy an…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure [Phase 2]
Phase 2 trial assessing dapagliflozin effect on submaximal exercise tolerance in heart failure with reduced ejection fraction (HFrEF) has co…
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction [Phase 3]
Phase 3 trial update for LCZ696 in Japanese patients with chronic heart failure with reduced ejection fraction (HF-rEF) has completed with r…
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study） [Phase 1, Phase 2]
Phase 1/2 trial investigating multi-intravenous infusion of umbilical cord mesenchymal stem cells in heart failure with reduced ejection fra…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF [Phase 3]
A Phase 3 trial evaluated glutamine as a myocardial protector in elective on-pump CABG surgery for patients with low ejection fraction; the …
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction [Phase 2]
Phase 2 trial evaluating intravenous APD418 for hemodynamic effects, safety, tolerability, and pharmacokinetics in adults with heart failure…
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF [Phase 4]
A Phase 4 clinical trial assessing the effects of ertugliflozin (ERTU-SODIUM) on sodium storage, interstitial volume, and plasma volume in h…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction [Phase 2]
Phase 2 trial update assessing safety, tolerability, and efficacy of IONIS-AGT-LRx in chronic heart failure with reduced ejection fraction h…
-
CLINICAL_TRIALS trial_result · 2023-08-15Clinical Trial Update: The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF) [Phase 4]
A Phase 4 clinical trial evaluating ferric derisomaltose for improving exercise capacity and quality of life in patients with acute heart fa…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction [Phase 4]
Phase 4 clinical trial update investigating sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
-
FDA approval · 2023-06-02FDA Approved: EPLERENONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' Original Application for a generic version of eplerenone (Inspra).
-
FDA label_change · 2023-05-10FDA Approved: VERQUVO — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Verquvo (vericiguat) from Merck Sharp & Dohme LLC to modify the product labeling.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction [Phase 4]
Phase 4 trial update assessing the effect of empagliflozin on NT-proBNP in patients with heart failure with reduced ejection fraction.
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) [Phase 4]
Phase 4 clinical trial update for the SAINTS B study evaluating screening in advanced heart failure patients with reduced ejection fraction;…
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure [Phase 3]
A Phase 3 trial evaluating the effect of omecamtiv mecarbil on exercise capacity in patients with heart failure with reduced ejection fracti…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot [Phase 2]
Pilot Phase 2 trial update on EVOlocumab in stable heart failure with reduced ejection fraction of ischemic etiology (EVO-HF).